Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CSGALNACT1 | Q8TDX6 | 9/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756344 | 1.00 | DGAT1 (0.49) | DGAT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1756420 | 0.91 | POLB (0.46) | DGAT1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1756419 | 0.91 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL1756443 | 0.91 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL1756272 | 0.85 | DGAT1 (0.67) | DGAT1CSGALNACT1 | |
| SCHEMBL1756203 | 0.84 | DGAT1 (0.52) | DGAT1MEN1KMT2ACSGALNACT1 | |
| SCHEMBL1756201 | 0.84 | DGAT1 (0.52) | DGAT1MEN1KMT2ACSGALNACT1 | |
| SCHEMBL1756256 | 0.83 | CSGALNACT1 (0.65) | DGAT1CSGALNACT1 | |
| SCHEMBL1756254 | 0.83 | CSGALNACT1 (0.65) | DGAT1CSGALNACT1 | |
| SCHEMBL1756422 | 0.82 | NPC1 (0.45) | NPC1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | claimed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | claimed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | claimed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | claimed |
| US-8722901-B2 | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity | Piramal Enterprises Limited (IN) | 2014-05-13 | — | — | US | disclosed |
| EP-2496564-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | Piramal Life Sciences Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | Piramal Enterprises Limited (IN) | 2012-08-23 | — | — | US | disclosed |
| WO-2011055289-A2 | HETEROARYL COMPOUNDS AS DGAT-1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214854-A1 | CARBOXY OXAZOLE OR THIAZOLE COMPOUNDS AS DGAT- 1 INHIBITORS USEFUL FOR THE TREATMENT OF OBESITY | DGAT1, DGAT2, DLAT | DGAT1 1/4885NPC1 278/4885RAB9A 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.